The MOMENTUM Study

  • Research type

    Research Study

  • Full title

    The Multiple OutcoMe EvaluatioN of radiation Therapy Using the MR-Linac Study

  • IRAS ID

    259162

  • Contact name

    Wes Dale

  • Contact email

    Wes.Dale@christie.nhs.uk

  • Sponsor organisation

    The Christie NHS Foundation Trust

  • Duration of Study in the UK

    4 years, 9 months, 1 days

  • Research summary

    The Magnetic Resonance-Linear accelerator (MR-Linac) consortium was formed as a collaboration between academic and industrial partners to facilitate evidence-based introduction of MR-Linac radiotherapy and to address how this could be used to improve patients’ cancer treatment.

    The Multiple OutcoMe EvaluatioN of radiation Therapy Using the MR-Linac (MOMENTUM) study was developed by the MR-Linac consortium and is an observational study designed as a registry of patients imaged and treated on the MR-Linac device to serve as a platform for other future studies.

    Adult cancer patients will be recruited across approximately 7 institutes in the UK, Netherlands, US and Canada initially. Participants will only follow standard of care according to their local institutes for Imaging Only or Imaging and Treatment with the MR-Linac device without the need for additional study visits. Participants of the Imaging Only and the Imaging and Treatment parts of the study are also given the opportunity to undergo additional research MRIs and questionnaires as part of the MOMENTUM study. Participation of the additional part of the study will not need additional study visits.

    Clinical and technical data collected from the MOMENTUM study will be used to enable the evaluation of safety and feasibility of new treatment strategies in other future studies. This will allow the continuous improvements in MR-Linac technology to improve the patient experience in MR-Linac radiotherapy.

  • REC name

    North West - Greater Manchester West Research Ethics Committee

  • REC reference

    19/NW/0475

  • Date of REC Opinion

    8 Aug 2019

  • REC opinion

    Favourable Opinion